UCL Division of Infection & Immunity

Athena SWAN Silver Award

External Seminar
1pm | 26 Feb | Cruciform LT2
Internal Seminar
1pm | 27 Feb | Pearson G22 LT

More I&I Events »


Our Research

immunology bench

Research in the Division spans Ageing to VZV Vaccine. Our research groups and centres belong to one of the following departments:


Professor Arne AKBAR (Ageing, Immune Regulation, Infection, Inflammation, T-Cells)

Professor Judy BREUER (VZV Vaccine)

Professor Benny CHAIN (HIV, Host-Pathogen Interaction, Immunotherapy, Infection, Inflammation, Innate Immunity) Research Group Page
Dr Helen DONOGHUE (Centre for Clinical Microbiology, Honorary)

Dr Ari FASSATI (Chemical Genetics, HIV, Host Factors, Transmissable Cancer)

Professor Richard GOLDSTEIN (Pathogen Evolution)

Professor Paul GRIFFTHS (CMV, Vaccination, Viruses)

Dr Joe GROVE (Immunology)

Dr Ravindra GUPTA (HIV, Viruses)

Dr Clare JOLLY (HIV, Host factors, T-Cells) Group Website

Professor Mala MAINI (HBV, Immunopathogenesis, Innate Immunity, Liver Immunology, T-Cells, Vaccinationi, Viral Immunology)

Dr Laura MCCOY (HIV, Vaccines)

Prof Timothy MCHUGH (Centre for Clinical Microbiology, TB, International Capacity Development)

Dr Richard MILNE (CMV, Vaccination, Viruses)

Professor Emma MORRIS (Gene Therapy, T-Cells, Tumour Immunology)

Dr Mahdad NOURSADEGHI (HIV) Research Group Page

Dr Dimitra PEPPA (HIV, NK Cells, Immunoregulation, HIV Immunopathogenesis)

Professor Deenan PILLAY (HIV, UCL Partners)

Dr Matthew REEVES (Virology)

Dr Helen ROWE (Virology, Stem cells) Research Group Website

Professor David SANSOM (Transplant Immunology)

Dr Benedict SEDDON (T-Cells)

Professor Hans STAUSS (Gene Therapy, T-Cells, Tumour Immunology, UCLP)

Dr Yashuhiro TAKEUCHI (Gene Therapy, Viruses)
Professor Richard TEDDER (HIV, Hepatitis B)

Professor Greg TOWERS (Herpes, HIV, Viruses) Group Website


Professor Lucy WALKER (Immune regulation, Diabetes) Lab website

Professor Robin WEISS (Emerging Infections, HIV, Influenza, Medical Mycology, Rabies) 

Professor Patricia WOO (Genomics, Rheumatology) 

Dr Jane ZUCKERMAN (Travel Medicine, Vaccinations) 

Professor Alimuddin ZUMLA (Centre for Clinical Microbiology)

Research Themes A-Z


[#top] [#A]A

Ageing (Akbar Group); 


Biofilms (UCL Biofilms Centre)


Chemical Genetics (Fassati Group (Wohl))
Cytomegalovirus (CMV) (Griffiths, CMV Research Group)



Emerging Infections (Weiss Group (Wohl))

[#G]G top

Gene Therapy (Professor Mary Collins; Stauss/Morris Group; Dr Yashuhiro Takeuchi (Wohl Virion Research Centre)
Genomics (Professor Paul KellamWoo Group)


HBV Immunopathogenesis (Maini Group)
Herpes (Towers Group)
HIV (Centre for Clinical Microbiology; Fassati Group (Wohl); ICH Immunobiology; Clare Jolly GroupPillay Group; Towers Group; Chain GroupWeiss Group (Wohl))
Host Factors (Fassati Group (Wohl); Clare Jolly Group; Dr Helen Rowe)
Host-Pathogen Interaction (Chain Group; Professor Paul Kellam; Dr Helen Rowe)


Immune Regulation (Akbar Group)
Immunobiology (ICH Immunobiology)
Immunotherapy (Chain Group)
Infection (Akbar Group; Centre for Clinical MicrobiologyChain Group)
Inflammation (Akbar Group; Chain Group)
Influenza (Weiss Group (Wohl))
Innate Immunity (Chain Group; Maini Group)
International Capacity Development (Centre for Clinical Microbiology)

[#L]L top

Liver Immunology (Maini Group)


Medical Mycology (Weiss Group (Wohl); Centre for Clinical Microbiology)
Microbiology (Centre for Clinical Microbiology)

Pathogen evolution (Professor Richard Goldstein)
Primary Immunodeficiency (Professor Bodo Grimbacher)


Rabies (Weiss Group (Wohl))
Respiratory Infection (Centre for Clinical Microbiology)
Rheumatology (Woo Group)

[#T]T top

TB (Centre for Clinical Microbiology)
T-Cells (Akbar Group; ICH Immunobiology; Jenner Group; Clare Jolly Group; Maini Group; Stauss/Morris Group)
Transmissible Cancer (Fassati Group (Wohl))
Transcription (Jenner Group; Dr Helen Rowe)
Travel Medicine (Dr Jane Zuckerman)
Tumour Immunology (Stauss/Morris Group)


Vaccination (Professor Mary Collins; Maini Group; Centre for Virology; Dr Jane Zuckerman);
Viral Immunology (Maini Group)
Viruses (Towers Group; Dr Yashuhiro Takeuchi (Wohl Virion Research Centre); CMV Research Group; Dr Helen Rowe)
VZV Vaccine (Breuer Group)


Research Projects

Collaborative Award in Science study: Why do Norovirus Pandemics Occur and how can we control them?

Date added: 09 November 2017

Prinicipal Investigator Professor Judy Breuer, UCL
Co-Investigators Professor Andrew Hayward (UCL), Professor Richard Goldstein (UCL), Professor John Edmunds (London School of Hygiene and Tropical Medicine), Dr David Allen (LSHTM), Professor Sarah O’Brien (University of Liverpool), Professor Ralph Baric (University of North Carolina)
Additional UCL team members Dr Sunando Roy, Ellen Fragaszy, Helena Tutill, Dr Rachel Williams (Project Manager), Dr Jenny Mindell
Project start/end dates January 2017-December 2020
Funder Wellcome Trust – Collaborative Award in Science

Project details

Norovirus is the commonest cause of vomiting and diarrhoea worldwide and the cause of more than 200,000 deaths every year affecting predominantly babies in developing countries. In the UK, norovirus outbreaks, particularly in winter months, are the most common reason for hospital ward closures, as well as affecting schools, care homes and even cruise ships. Although new vaccines are being developed, the worldwide spread every two to five years of a new ‘pandemic’ norovirus strain may reduce their effectiveness.

In this 4-year multi-disciplinary study, we propose to analyse noroviruses collected over the last 20 years to work out how many different strains a vaccine would need to protect against. Using information on where and when each norovirus was collected will help us understand the time and place of origin for each new pandemic strain. By measuring antibodies to norovirus in stored blood samples from the same time period, we will work out how quickly new norovirus pandemics spread and whether children are the first to be infected.

We will analyse all the data together to work out who should be vaccinated, how often and whether we can predict which strains are more likely to cause problems.

Next generation sequencing of norovirus will be carried out using the automated high throughput pipeline within the UCL Pathogen Genomic Unit facility.

Contact for further information: Rachel Williams

ICONIC: Infection Response through Virus Genomics

Date added: 24 April 2014

ICONIC is a 3-year research Health Innovation Challenge Fund project funded by the Department of Health and the Wellcome Trust running from October 2013.

The project is a collaborative effort led by UCL and involving the Wellcome Trust Sanger Institute, UCLH, PHE, Barts Health, HCVRUK and the Universities of Edinburgh and Nottingham.

ICONIC aims to utilise next generation sequencing technology, in order to (i) stratify therapy (HIV and Hepatitis C virus used as a case example), (ii) guide hospital infection control responses (Norovirus), and (iii) inform surveillance and epidemiological responses to community outbreaks (Measles and Influenza viruses).

ICONIC will advance the capacity for embedding this new technology within the UK diagnostic environment, in a sustainable and cost effective manner. In so doing, we aim to embed into the NHS the ability to rapidly respond to new and emerging viral infections in the future. 

I&I Project Personnel: Prof Paul Kellam, Dr Zisis Kozlakidis and Dr Dan Frampton.

Contact Name: Zisis Kozlakidis (email)

RID-RTI: Rapid Diagnosis of Respiratory Tract Infections

Date added: 13 November, 2013

RiD-RTI is a 3-year research project funded by the European Commission Seventh Framework Programme running from 2012. 

It is a unique multi-centre project led and coordinated by UCL consisting additionally of two SMEs, Mobidiag (Finland) and Genewave (France); another academic partner, NUIG Galway (Ireland); and a clinical partner, UCLH (UK).

The aims of the RiD-RTI project are to develop and evaluate three diagnostics products for the rapid diagnosis of Respiratory Tract Infections (RTIs), based on a novel “sample-in, answer-out” diagnostic platform. The diagnostic products will be designed to be ‘near patient’, reliable, cost-effective and user friendly allowing for the rapid (< 2 hrs) and accurate detection, identification, quantification (for selected targets) and molecular drug susceptibility testing of RTIs.

More information can be sought from the project website which launched earlier this month: www.rid-rti.eu.

Key UCL personnel working on the project are:
Professor Alimuddin Zumla, Principal Investigator (email)
Dr Virve (Vicky) Enne, Scientific Coordinator (email)
Dr Ljuban Grgic, Project Administrator and coordinator (email)

PanACEA (Pan African Consortium for the Evaluation of Antituberculosis Antibiotics)

Date: 5 August, 2013

This research programme is made up of a consortium of scientists from more that 14 countries with skills in clinical trials, pulmonology, mycobacteriology, pharmacokinetics, statistics and delivery of clinical service. This joint initiative comes from the recognition that only by working together across countries and disciplines can the spectre of TB be controlled.

The programme website launched this month can much more information:

Work at UCL is led by Professor Tim McHugh, Centre for Clinical Microbiology (email).

Sequencing Facilities: Pathogen Genomics Unit

UCL-UCLH Pathogen Genomics Unit

The UCL-UCLH Pathogen Genomics Unit (PGU) is an initiative and collaboration between UCL (Professor Judith Breuer, Dr Mahdad Noursadeghi) and UCLH (Dr Vanya Gant, Dr Eleni Nastouli) established by grants from the Medical Research Council (Breuer, Noursadeghi) and the UCL-UCLH Biomedical Research Centre.

UCL Pathogen Genomics Unit [PGU]

ULCH Pathogen Genomics Unit [PGU]

Page last modified on 10 jan 18 11:41